WX
WuXi Biologics (Cayman) Inc.
WXIBF · OTC
$6.77 +0.00% (+$0.00)
1M +12.65%
Market Cap ¥187.9B
P/E Ratio 39.30x
Div. Yield -
ROE 10.50%
Bulios Fair Price
$4.19
38.1% downside
Current Price
$6.77
Undervalued Fair Value Overvalued
According to Bulios Fair Price, WXIBF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
9/9Valuation
20 /100
Expensive PEG 0.93x
P/S 8.85x
P/B 3.98x
Growth
60 /100
Stable Rev. growth 11.61%
Book val. growth 10.49%
EPS growth 3.51%
Profitability
92 /100
Strong Net margin 22.53%
Op. margin 30.50%
FCF margin 13.19%
Quality
49 /100
Average ROE 10.50%
ROA 7.50%
Asset turnover 0.33x
Debt
100 /100
Low Current ratio 3.14x
Int. coverage 46.46x
Net debt/EBITDA -0.75x
Stability
88 /100
Stable Rev. volatility 2.02%
EPS volatility 34.04%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about WXIBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Zhisheng Chen
Employees
13,252
Headquarters
Wuxi
Upcoming events
23 MAR
Earnings
Upcoming earnings report